Kyle Z. Pasquariello

Kyle Z. Pasquariello

Auto-generated profile, based on publicly available information

Kyle Z. Pasquariello

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
EHElizabeth R. Hayden
Elizabeth R. Hayden
MCMingqing Chen
Mingqing Chen
KPKyle Z. Pasquariello
Kyle Z. Pasquariello
AGAlice A. Gibson
Alice A. Gibson
JPJames J. Petti
James J. Petti
JSJason Sprowl
Jason Sprowl
Purpose: OATP1B1 (SLCO1B1) is the most abundant and pharmacologically relevant uptake transporter in the liver and a key mediator of xenobiotic clearance. However, the regulatory mechanisms that determine OATP1B1 activity remain uncertain, and as a result, unexpected drug–drug interactions involving OATP1B1 substrates continue to be reported, including several involving tyrosine kinase inhibitors (TKI).Experimental Design: OATP1B1-mediated activity in overexpressing HEK293 cells and hepatocytes was assessed in the presence of FDA-approved TKIs, while rosuvastatin pharmacokinetics in the presence of an OATP1B1 inhibiting TKI were measured in vivo. Tyrosine phosphorylation of OATP1B1 was determined by LC/MS-MS–based proteomics and transport function was measured following exposure to siRNAs targeting 779 different kinases.Results: Twenty-nine of 46 FDA-approved TKIs studied significantly inhibit OATP1B1 function. Inhibition of OATP1B1 by TKIs, such as nilotinib, is predominantly noncompetitive, can increase systemic concentrations of rosuvastatin in vivo, and is associated with reduced phosphorylation of OATP1B1 at tyrosine residue 645. Using genetic screens and functional validation studies, the Src kinase LYN was identified as a potential regulator of OATP1B1 activity that is highly sensitive to inhibition by various TKIs at clinically relevant concentrations.Conclusions: A novel kinase-dependent posttranslational mechanism of OATP1B1 activation was identified and interference with this process by TKIs can influence the elimination of a broad range of xenobiotic substrates.

31 March 2023
Verified
Other
Open access
EHElizabeth R. Hayden
Elizabeth R. Hayden
MCMingqing Chen
Mingqing Chen
KPKyle Z. Pasquariello
Kyle Z. Pasquariello
AGAlice A. Gibson
Alice A. Gibson
JPJames J. Petti
James J. Petti
JSJason A. Sprowl
Jason A. Sprowl
Assessment of lapatinib or trametinib as OATP1B1 substrates. (A) Percent uptake of 3H-lapatinib (1 µM) in OATP1B1 overexpressing HEK293 cells relative to uptake in HEK293 cells transfected with a vector control (VC) (n=3, from a single experiment). (B) Lineweaver-Burke plot for OATP1B1-dependent uptake in HEK293-OATP1B1 cells treated with various concentrations of trametinib (0 - 5 µM) and 8FcA (0 - 40 µM) (n=9, and a combination of 3 independent experiments) . * denotes P < 0.001 vs VC. All values represent mean {plus minus} SEM.

31 March 2023
Verified
Other
Open access
EHElizabeth R. Hayden
Elizabeth R. Hayden
MCMingqing Chen
Mingqing Chen
KPKyle Z. Pasquariello
Kyle Z. Pasquariello
AGAlice A. Gibson
Alice A. Gibson
JPJames J. Petti
James J. Petti
JSJason A. Sprowl
Jason A. Sprowl
A structural model of OATP1B1. The model was generated by Phyre2 and presented as a cartoon. Y640 and Y645 are highlighted in blue and the image was produced with PyMOL.

31 March 2023
Verified
Other
Open access
EHElizabeth R. Hayden
Elizabeth R. Hayden
MCMingqing Chen
Mingqing Chen
KPKyle Z. Pasquariello
Kyle Z. Pasquariello
AGAlice A. Gibson
Alice A. Gibson
JPJames J. Petti
James J. Petti
JSJason A. Sprowl
Jason A. Sprowl
Influence of TKIs on OATP1B1-dependent uptake or substrate disposition. (A) Uptake of 3H-EβG (2 µM, 2 min) in OATP1B1 overexpressing HEK293 cells in the presence or absence of select individual FDA approved TKIs (10 μM) identified as positive or negative OATP1B1 inhibitors, following pre-treatment with TKIs for 15 minutes (n=6) (A). Data are presented as a percent of OATP1B1 activity compared to treatment with DMSO (Vehicle). *denotes P < 0.05 vs vehicle and all values represent mean {plus minus} SEM and the experiment was repeated on two separate occasions. (B) Time dependent plasma concentration of methotrexate following injection (10 mg/kg, i.v.) in the presence or absence of a 30-minute pre-treatment with nilotinib (37.5 mg/kg, p.o.). *denotes P < 0.05 vs vehicle and all values represent mean {plus minus} SEM of three male mice.

31 March 2023
Verified
Other
Open access
EHElizabeth R. Hayden
Elizabeth R. Hayden
MCMingqing Chen
Mingqing Chen
KPKyle Z. Pasquariello
Kyle Z. Pasquariello
AGAlice A. Gibson
Alice A. Gibson
JPJames J. Petti
James J. Petti
JSJason A. Sprowl
Jason A. Sprowl
A structural model of OATP1B1. The model was generated by Phyre2 and presented as a cartoon. Y640 and Y645 are highlighted in blue and the image was produced with PyMOL.

31 March 2023
Verified
Other
Open access
EHElizabeth R. Hayden
Elizabeth R. Hayden
MCMingqing Chen
Mingqing Chen
KPKyle Z. Pasquariello
Kyle Z. Pasquariello
AGAlice A. Gibson
Alice A. Gibson
JPJames J. Petti
James J. Petti
JSJason A. Sprowl
Jason A. Sprowl
Mean {plus minus} SEM change of 8FcA uptake (Mean difference) in OATP1B1 overexpressing HEK293 cells between vehicle (DMSO) and exposure to FDA approved TKIs. Statistical significance was measured by ANOVA and Fisher's LSD test.